FDA Backs Testing of Device Once Flagged for Covid Speculation
This article is for subscribers only.
As far back as January, stock traders were latching onto Aethlon Medical Inc. and its experimental Hemopurifier device as a potential treatment for the novel coronavirus. After shares quadrupled that month from less than $1 each, market speculation got so heated that the U.S. Securities and Exchange Commission suspended trading in the stock for two weeks.
In early March, the company put out a cautious statement, saying it wasn’t sure if the Hemopurifier would help with Covid-19, and even then potentially only in the sickest patients.